Skip to main content
UniHealth

Doctor search

Fabio Massaiti Iwamoto, MD

Neurology · New York

NPI 1053623934

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Offices
2

Offices

2 locations · Trustees of Columbia University in the City of New York · 2,262 clinicians in this group

Looking this up.

Hospitals listed: New York-Presbyterian Hospital. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Iwamoto’s office to ask if they take your plan before you enroll.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • New York-Presbyterian HospitalNew York, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of New York Presbyterian Healthcare System, which runs 8 hospitalsHome of Herbert Irving Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 72% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 15.2 (13.8 to 16.7) · 1,897 cases, Jan 2024 – Dec 2024Better than the national rate — Abdominopelvic accidental puncture or laceration rate: 0.35 (0 to 0.86) · 10,364 cases, Jul 2022 – Jun 2024Better than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.4 (0.3 to 0.51), Jul 2022 – Jun 2024Better than the national rate — In-hospital fall-associated fracture rate: 0.14 (0.03 to 0.25) · 52,654 cases, Jul 2022 – Jun 2024Better than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 1.48 (0.6 to 2.36) · 14,926 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative acute kidney injury requiring dialysis rate: 0.48 (0 to 1.06) · 8,078 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative hemorrhage or hematoma rate: 0.94 (0.21 to 1.66) · 12,529 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 6.15 (4.51 to 7.79) · 8,277 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 1.66 (0.42 to 2.91) · 8,436 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.09 (0 to 0.3) · 44,511 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.575, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.632, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.22, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.743, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.6 (2.9 to 4.4) · 1,897 cases, Jan 2024 – Dec 2024Better than the national rate — Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies): 10.6 (8.9 to 12.6) · 7,950 cases, Jan 2022 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.6 (0.6 to 0.7) · 4,225 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for New York-Presbyterian Hospital

Behind the star rating — Deaths: 6 better, 2 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 3 better, 6 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at New York-Presbyterian Hospital
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits15.2 (13.8 to 16.7) · 1,897 casesWorseJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.35 (0 to 0.86) · 10,364 casesBetterJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.4 (0.3 to 0.51)BetterJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.14 (0.03 to 0.25) · 52,654 casesBetterJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths1.48 (0.6 to 2.36) · 14,926 casesBetterJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.48 (0 to 1.06) · 8,078 casesBetterJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths0.94 (0.21 to 1.66) · 12,529 casesBetterJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths6.15 (4.51 to 7.79) · 8,277 casesBetterJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths1.66 (0.42 to 2.91) · 8,436 casesBetterJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.09 (0 to 0.3) · 44,511 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.575BetterOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.632BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.22BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.743BetterOct 2024 – Sep 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits3.6 (2.9 to 4.4) · 1,897 casesBetterJan 2024 – Dec 2024
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits10.6 (8.9 to 12.6) · 7,950 casesBetterJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.6 (0.6 to 0.7) · 4,225 casesBetterJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths156.83 (135.92 to 177.74) · 798 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.7 · 382 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths5.7 · 574 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.6 · 616 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.9 · 2,532 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.9 · 3,140 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths7.7 · 1,821 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths1.8 · 24,470 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.11 (0 to 0.22) · 48,588 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths0.84 (0 to 1.9) · 3,187 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 1,240 casesNoneApr 2023 – Mar 2025
SSI - Abdominal HysterectomyInfections0.314No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.717No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.6 · 1,045 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.4 · 5,234 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits11 · 686 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits3 · 2,938 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits13.4 · 3,258 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.4 · 5,005 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits5.5 · 1,230 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.9 · 411 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.6 · 1,226 casesNoneJul 2023 – Jun 2025

What patients said (2,640 patients answered, 20% of those asked)

Patient survey stars by topic at New York-Presbyterian Hospital
Cleanliness3
Nurse communication3
Doctor communication3
Communication about medicines3
Discharge information3
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at New York-Presbyterian Hospital
Room was "always" clean65%
Nurses "always" communicated well76%
Doctors "always" communicated well78%
Staff "always" explained59%
Yes, staff "did" give patients this information85%
Yes, staff "did" give patients information about help after discharge84%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully77%
Doctors "always" treated them with courtesy and respect84%
Patients who gave a rating of "9" or "10" (high)69%
Staff "always" explained new medications74%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully72%
Nurses "always" treated them with courtesy and respect82%
"Always" quiet at night49%
"YES", patients would definitely recommend the hospital72%
Staff "always" explained possible side effects45%
Yes, staff "did" give patients information about possible symptoms87%

Original Medicare doctor bills

$82,582

Medicare paid this office $82,582 for 114 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)83$57,293$165
Return visit (30+ min)52$11,166$119
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's104$6,860$15
New patient visit (60+ min)13$2,748$211
Short return visit (20+ min)12$2,435$81

Who their Medicare patients are

114 Original Medicare patients in 2024. Average age 70 · Women 47% · Also on Medicaid 23% · Health risk score 2.05. Above the middle of the specialty; the typical neurology clinician is at 1.61.

Conditions among them: High blood pressure 61% · Stroke 33% · Diabetes 30% · Depression 24% · Coronary heart disease 18% · Cancer 18% · Chronic kidney disease 17% · Atrial fibrillation 16% · Heart failure 15% · Dementia 13% · COPD 11%.

The office billed $376,220, Medicare allowed $104,249 and paid $82,582; for 1,119 services of 11 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20241141,119702.05$376,220$82,582
2023108448691.85$301,580$64,539
2022112495691.73$325,000$68,515
202199513691.55$269,590$66,649
202085427691.57$191,370$45,341
201994378701.94$169,835$36,740
201898456671.89$210,875$43,908
2017100483682.04$220,450$45,665
201694464661.63$185,750$42,942
201591397702.34$151,850$39,729
201476328712.02$128,268$31,963
201399539681.93$247,450$55,139

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 4 services

Original Medicare services billed in 2023
Long return visit (40+ min)79$47,958$156
Return visit (30+ min)35$7,086$118
New patient visit (60+ min)20$4,097$195
Short return visit (20+ min)16$3,432$84

2022: 4 services

Original Medicare services billed in 2022
Long return visit (40+ min)82$46,669$156
Return visit (30+ min)53$10,995$107
New patient visit (60+ min)21$4,121$196
Initial hospital care with moderate level of medical decision making at least 75 minutes13$2,278$175

2021: 4 services

Original Medicare services billed in 2021
Long return visit (40+ min)54$28,019$170
Return visit (30+ min)71$25,627$116
Short return visit (20+ min)34$7,459$79
New patient visit (60+ min)21$4,289$204

2020: 4 services

Original Medicare services billed in 2020
Return visit (30+ min)64$20,484$96
Long return visit (40+ min)38$15,412$135
Short return visit (20+ min)32$5,032$70
New patient visit (60+ min)17$3,311$195

2019: 4 services

Original Medicare services billed in 2019
Return visit (30+ min)62$23,349$95
Short return visit (20+ min)14$3,657$65
Long return visit (40+ min)16$3,439$132
New patient visit (60+ min)13$2,442$188

2018: 5 services

Original Medicare services billed in 2018
Return visit (30+ min)62$26,316$94
Long return visit (40+ min)27$4,922$126
Short return visit (20+ min)20$3,231$63
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes14$2,460$117
New patient visit (60+ min)12$2,100$175

2017: 7 services

Original Medicare services billed in 2017
Return visit (30+ min)61$27,473$94
Short return visit (20+ min)25$5,061$65
Long return visit (40+ min)24$4,150$130
Initial hospital care with moderate level of medical decision making at least 75 minutes21$4,145$180
New patient visit (60+ min)16$2,688$168
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes16$1,113$62
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes12$664$35

2016: 3 services

Original Medicare services billed in 2016
Return visit (30+ min)74$27,762$91
Long return visit (40+ min)28$5,656$126
Short return visit (20+ min)27$4,239$64

2015: 5 services

Original Medicare services billed in 2015
Return visit (30+ min)56$23,215$92
Long return visit (40+ min)25$6,777$128
Initial hospital care with moderate level of medical decision making at least 75 minutes22$4,510$180
Short return visit (20+ min)18$1,919$64
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes13$895$64

2014: 4 services

Original Medicare services billed in 2014
Return visit (30+ min)56$20,090$90
Long return visit (40+ min)29$5,493$119
New patient visit (60+ min)22$3,890$177
Short return visit (20+ min)20$1,949$59

2013: 7 services

Original Medicare services billed in 2013
Return visit (30+ min)56$23,271$92
Long return visit (40+ min)42$10,808$126
Initial hospital care with moderate level of medical decision making at least 75 minutes31$7,399$172
New patient visit (60+ min)26$4,541$175
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$3,414$85
Short return visit (20+ min)15$2,279$60
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes12$1,471$61

Money from drug and device companies

$2,181 in 2025

Industry payments by year
202527None$2,181
202437$508$9,244
2023118$7,200$8,823
202211$578$578
202023$6,500$6,650
201929$3,600$3,908

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Telix PharmaceuticalsIlluccix$2,083
6 payments
  • Meals for Illuccix · 2025-03-08 · $72
  • Meals for Illuccix · 2025-03-08 · $63
  • Meals for Illuccix · 2025-03-08 · $95
  • Travel for Illuccix · 2025-03-08 · $1,320
  • Meals for Illuccix · 2025-03-07 · $124
  • Travel for Illuccix · 2025-03-07 · $410
Caris MPIMi Cancer Seek$97
1 payment
  • Meals for Mi Cancer Seek · 2025-11-21 · $97
See all 7 published payments
Every published payment
Caris MPIMeals · 2025-11-21Mi Cancer Seek$97
Telix PharmaceuticalsMeals · 2025-03-08Illuccix$72
Telix PharmaceuticalsMeals · 2025-03-08Illuccix$63
Telix PharmaceuticalsMeals · 2025-03-08Illuccix$95
Telix PharmaceuticalsTravel · 2025-03-08Illuccix$1,320
Telix PharmaceuticalsMeals · 2025-03-07Illuccix$124
Telix PharmaceuticalsTravel · 2025-03-07Illuccix$410
See earlier years (2024, 2023, 2022, 2020, 2019)

2024: $9,244

Payments by company in 2024
F. Hoffmann-La Roche AGNone$8,616
5 payments
  • Travel · 2024-04-23 · $6,399
  • Travel · 2024-04-23 · $664
  • Travel · 2024-04-23 · $1,127
  • Travel · 2024-04-23 · $147
  • Meals · 2024-04-23 · $279
ZOLL MedicalDefibrillator$508
1 payment
  • Consulting for Defibrillator · 2024-09-04 · $508
NovocureOptune$119
1 payment
  • Meals for Optune · 2024-09-19 · $119

2023: $8,823

Payments by company in 2023
NovocureOptune$8,823
18 payments
  • Honoraria for Optune · 2023-12-15 · $1,200
  • Honoraria for Optune · 2023-08-30 · $6,000
  • Travel for Optune · 2023-08-30 · $328
  • Meals for Optune · 2023-08-30 · $40
  • Meals for Optune · 2023-06-30 · $11
  • Meals for Optune · 2023-06-30 · $15
  • Meals for Optune · 2023-06-30 · $26
  • Meals for Optune · 2023-06-30 · $27
  • Meals for Optune · 2023-06-30 · $29
  • Meals for Optune · 2023-06-30 · $39
  • Meals for Optune · 2023-06-30 · $59
  • Travel for Optune · 2023-06-30 · $162
  • Meals for Optune · 2023-06-30 · $95
  • Meals for Optune · 2023-06-24 · $124
  • Travel for Optune · 2023-06-10 · $18
  • Travel for Optune · 2023-06-10 · $44
  • Travel for Optune · 2023-06-08 · $3
  • Travel for Optune · 2023-06-08 · $602

2022: $578

Payments by company in 2022
MedtronicNone$578
1 payment
  • Consulting · 2022-03-07 · $578

2020: $6,650

Payments by company in 2020
Merck Sharp & DohmeNone$5,650
2 payments
  • Travel · 2020-01-29 · $150
  • Consulting · 2020-01-29 · $5,500
NovocureOncology$1,000
1 payment
  • Consulting for Oncology · 2020-10-08 · $1,000

2019: $3,908

Payments by company in 2019
NovocureOncology$3,715
5 payments
  • Honoraria for Oncology · 2019-07-26 · $3,600
  • Travel for Oncology · 2019-07-26 · $39
  • Meals for Oncology · 2019-07-18 · $12
  • Meals for Oncology · 2019-07-18 · $30
  • Meals for Oncology · 2019-07-18 · $34
Merck Sharp & DohmeNone$193
4 payments
  • Meals · 2019-11-21 · $30
  • Meals · 2019-11-21 · $49
  • Meals · 2019-11-21 · $50
  • Meals · 2019-11-21 · $64

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
PFIZER INC. · A Phase 1ab Openlabel Master Study of Pf07799544 As A Singleagent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors · 2024Their institution$262,149
Otsuka Pharmaceutical Co., Ltd. · Study of Astx295 in Patients With Solid Tumors With Wild-Type P53 · 2023Their institution$217,646
Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2023Their institution$215,626
Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2022Their institution$63,052
Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2021Their institution$50,072
Novocure GmbH · Ef-41 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune (Ttfields, 200 Khz) Concomitant With Maintenance Temozolomide and Pembrolizumab Versus Optune Concomitant With Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma · 2025Their institution$44,344
PFIZER INC. · A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of Pf06840003 in Patients With Malignant Gliomas · 2019Their institution$40,113
E.R. Squibb & Sons, L.L.C. · Ph Iib Cns Lymphoma Mono · 2022Their institution$37,974
TAIHO ONCOLOGY, INC. · Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of Astx295 in Subjects With Wild-Type Tp53 Advanced Solid Tumors · 2024Their institution$37,838
E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Methylated Nivo Mono Chemo Rt · 2020Their institution$32,778
Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2024Their institution$31,839
E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Unmethylated Mgmt (Nivo Mono Rt) - A Randomized Phase 3 Open Label Study of Nivolumab Vs Temozolo Mide Each in Combination With Radiat Ion Therapy in Newly Diagnosed Adult Subjects With Unmethylated Mgmt (Tumor O-6 Methylguanine Dna Meth · 2023Their institution$27,577
E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Methylated Nivo Mono Chemo Rt · 2019Their institution$26,847
E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Unmethylated Mgmt Nivo Mono Rt · 2019Their institution$25,740
Novocure GmbH · Ef-32 Trident A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant With Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma · 2025Their institution$17,169
E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Methylated Nivo Mono Chemo Rt - A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Co Mbined With Nivo Lumab Or Placebo in Newly Diagnosed Adult Subjects With Mgmt -Methylated (Tumor O6-Methylguanine Dna Methy · 2022Their institution$15,820
E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Methylated (Nivo Mono Chemo Rt) - A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Co Mbined With Nivo Lumab Or Placebo in Newly Diagnosed Adult Subjects With Mgmt -Methylated (Tumor O6-Methylguanine Dna Met · 2023Their institution$13,690
TAIHO ONCOLOGY, INC. · Study of Astx295 in Patients With Solid Tumors With Wild-Type P53 · 2024Their institution$11,110
E.R. Squibb & Sons, L.L.C. · Ph III 1l Gbm Unmethylated Mgmt Nivo Mono Rt · 2022Their institution$9,820
E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Unmethylated Mgmt Nivo Mono Rt · 2020Their institution$9,620
E.R. Squibb & Sons, L.L.C. · Phase Iib Primary Cns and Testicular Lymphoma (Mono) · 2024Their institution$4,977
E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Methylated Nivo Mono Chemo Rt · 2021Their institution$4,652
E.R. Squibb & Sons, L.L.C. · Phase Iib Primary Cns and Testicular Lymphoma Mono · 2020Their institution$4,248
E.R. Squibb & Sons, L.L.C. · Phase Iib Primary Cns and Testicular Lymphoma Mono · 2021Their institution$2,000
TAIHO ONCOLOGY, INC. · Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of Astx295 in Subjects With Wild-Type Tp53 Advanced Solid Tumors · 2025Their institution$1,386
E.R. Squibb & Sons, L.L.C. · Phase Iib Primary Cns and Testicular Lymphoma Mono · 2019Their institution$628
PFIZER INC. · A Phase 1ab Openlabel Master Study of Pf07799544 As A Singleagent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors · 2023Their institution$404

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
100.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1053623934
Licence
NY 264009
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Neurology (2084N0400X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2010-07-08
NPI last updated
2026-07-02
NPI record certified
2026-07-02

This is when the NPI record was last certified, not a medical board exam.